银杏达莫联合注射用小牛血去蛋白提取物治疗急性脑梗死的临床效果

Abstract
Figure/Table
References (23)
Related Citation (8)

Download: PDF (494 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of Ginkgo bilobate extract combined with deproteinized calf blood extratives for injection in the treatment of acute cerebral infarction. Methods A total of 80 patients with acute cerebral infarction admitted to Shenzhen People′s Hospital from February 2013 to December 2017 were selected. Patients were divided into control group (40 cases) and study group (40 cases) by random number table method, and the control group was treated with deproteinized calf blood extratives for injection, while the study group was treated with Ginkgo bilobate extract on the basis of the control group treatment. The clinical efficacy of the two groups after treatment was compared. Serological indicators were compared between the two groups before and after treatment, including the serum levels of interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), endothelin-1 (ET-1), nitric oxide (NO), and hemorheological index. The incidence of adverse reactions during the treatment of the two groups was recorded and compared. Results The total effective rate of the study group was significantly higher than that of the control group (P ＜ 0.05). After treatment, the levels of IL-6, hs-CRP, TNF-α and ET-1 in the two groups were lower than those before treatment, and those in the study group were lower than those in the control group (P ＜ 0.05); NO was higher than that before treatment, and that in the study group was higher than that in the control group (P ＜ 0.05). After treatment, the plasma viscosity, blood viscosity, hematocrit and erythrocyte aggregation index of the two groups were lower than those before treatment, and those in the study group were lower than those in the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P ＞ 0.05). Conclusion Ginkgo bilobate extract combined with deproteinized calf blood extratives for injection is effective in the treatment of acute cerebral infarction. It can maintain the stability of hemorheological index, improve the serological indicator of the patients, and the therapy does not increase the incidence of adverse reactions. It has certain clinical application value.

Key words： Ginkgo bilobate extract Deproteinized calf blood extratives for injection Acute cerebral infarction

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Heming1 GAO Xia1 ZHANG Rui1 CHEN Shi1 ZOU Liangyu2

Cite this article:

HUANG Heming1 GAO Xia1 ZHANG Rui1 CHEN Shi1 ZOU Liangyu2. Clinical efficacy of Ginkgo bilobate extract combined with deproteinized calf blood extratives for injection in the treatment of acute cerebral infarction[J]. 中国医药导报, 2019, 16(5): 47-50.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I5/47

[1] 陈兴东，罗伟良.成人房颤急性脑梗死与非房颤急性脑梗死住院患者肾功能不全的对照分析[J].实用医学杂志，2017，33（7）：1040-1043.
[2] Fukuoka T，Hayashi T，Kato Y，et al. Clinical review of 24 patients with acute cholecystitis after acute cerebral infarction [J]. Intern Med，2014，53（12）：1321-1323.
[3] 张颖.急性脑梗死患者急性期血清OPN、氧化应激水平的变化及其与神经损伤和预后的关系[J].广东医学，2017， 38（9）：1386-1389.
[4] 任宏伟，茅利玉，钱华，等.舒血宁注射液联合小牛血去蛋白提取物对脑梗死恢复期患者血清IGF-1、IL-1及ICAM-1水平影响研究[J].中国生化药物杂志，2015，35（11）：133-135.
[5] Chen X，Bi H，Zhang M，et al. Research of Sleep Disorders in Patients with Acute Cerebral Infarction [J]. J Stroke Cerebrovasc Dis，2015，24（11）：2508-2513.
[6] 乔媛，储秋萍.3种依达拉奉联合用药方案治疗急性脑梗死的最小成本分析[J].中国药房，2016，27（5）：581-583.
[7] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[8] 黎宏庄.rt-PA静脉溶栓治疗心源性及非心源性脑梗死的疗效对比观察[J].山东医药，2016，56（27）：50-52.
[9] Blech B，O'Carroll C. Acute Right Middle Cerebral Artery Occlusion Resulting in Acute Systolic Heart Failure，CerebralT-Waves，and QTc Prolongation：A Case Report [J]. Neurologist，2018，23（4）：135-137.
[10] 王金成，姜立刚，李海平，等.急性脑梗死患者血清正五聚体蛋白3、C反应蛋白水平变化及临床意义[J].中国老年学杂志，2018，38（1）：71-73.
[11] 黄荣娥，张学川.急性脑梗死患者血清和肽素、NT-proBNP水平变化及其临床意义[J].中国实验诊断学，2016， 20（3）：409-412.
[12] Zhu H，Zhao T，Liu J. Role of Paraoxonase 1 Activity and Oxidative/Antioxidative Stress Markers in Patients with Acute Cerebral Infarction [J]. Clin Lab，2018，64（6）：1049-1053.
[13] 许杭雨，徐浩，张辰颉，等.急性脑梗死患者超敏C反应蛋白表达水平及临床意义研究[J].重庆医学，2017，46（26）：3691-3693.
[14] Iso T，Yanagawa Y，Takeuchi I，et al. Concomitance Acute Cerebral Infarction and Remote Intra-Cerebral Hemorrhaging on Arrival [J]. J Emerg Trauma Shock，2018， 11（2）：149-150.
[15] 王晓萍，彭军.川芎嗪联合小牛血去蛋白提取物治疗椎基底动脉供血不足的临床疗效研究[J].中国生化药物杂志，2016，36（2）：148-150.
[16] 张垣，黄建平，陈炳，等.小牛血去蛋白提取物联合高压氧对重型颅脑损伤患者hs-CRP、TNA-α、IL-6的影响及其临床疗效[J].中国生化药物杂志，2016，36（4）：170-172.
[17] 王盛，王朝平，陈太董，等.神经节苷脂联合银杏达莫对颅脑损伤患者的临床研究[J].中国临床药理学杂志，2016， 32（12）：1075-1077.
[18] 朱风俊，贾东佩，张群英，等.阿托伐他汀钙对脑梗死的治疗作用及对Hs-CRP、IL-6、TNF-α炎症因子的影响[J].中国现代医学杂志，2014，24（20）：81-84.
[19] 李素萍，张海丽.急性脑梗死患者早期血浆ET-1、hs-CRP水平变化的相关研究[J].武警后勤学院学报：医学版，2013，22（10）：927-928.
[20] 刘昌云，陈技挺，黄华品.丁苯酞注射液对急性脑梗死患者血清NO和NOS表达及临床疗效的影响[J].中国老年学，2013，33（14）：3448-3449.
[21] 牛强.依达拉奉联合银杏达莫治疗脑梗死的临床疗效[J].中国实用神经疾病杂志，2016，19（8）：11-13.
[22] 章湉.银杏达莫注射液治疗中青年急性脑梗死的临床研究[J].中国当代医药，2018，25（1）：132-134，138.
[23] 曹开端.银杏达莫注射液治疗急性脑梗死的临床研究[J].药品评价，2017，14（8）：36-38.